Effect of Parenteral Glutamine on Myocardial Injury and Inflammation Biomarkers
Insufficiency;Cardiac
About this trial
This is an interventional prevention trial for Insufficiency;Cardiac focused on measuring Cardiovascular surgery, Glutamine, Heart damage markers
Eligibility Criteria
Inclusion Criteria: Patients with a diagnosis of ischemic heart disease who will undergo surgery to CRC. Age 40 to 70 years. BMI from 18.5 to 29.9 kg / m2 Stable renal function with a serum creatinine less than 1.5 mg / dl. Complete and signed informed consent. Exclusion Criteria: Left ventricular ejection fraction <40%. Pre-existing disease such as: Renal impairment under substitute treatment (peritoneal dialysis or hemodialysis), Hepatic impairment, Human immunodeficiency syndrome, Viral liver disease (due to virus B and C). Patients with previous cardiac surgery. Emergency surgery or myocardial ischemia in progress. Known allergy to the supplement to be used in the study Alcohol abuse or drug use 1 month before surgery
Sites / Locations
- Instituto Mexicano del Seguro Social
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Placebo Comparator
Experimental
Placebo Comparator
Patients on bypass with cardiopulmonary bypass +gluta
Patients on bypass + cardiopulmonary bypass + glutamine
patients without bypass + cardiopulmonary bypass +glutamine
Patients without bypass + cardiopulmonary bypass +placebo
Patients operated on bypass with cardiopulmonary bypass + glutamine
Patients operated on bypass with cardiopulmonary bypass + glutamine
Patients operated without bypass with cardiopulmonary bypass + glutamine
Patients operated without bypass with cardiopulmonary bypass + placebo